[Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer].
Buecher
B
B
Service d'Hépato-Gastroentérologie, CHU-Hôtel-Dieu, Nantes, France. bruno.buecher@chu-nantes.fr
Heymann
M F
MF
Blottière
H M
HM
D025601:Adenomatous Polyposis Coli Protein; D017209:Apoptosis; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D003598:Cytoskeletal Proteins; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics; D008565:Membrane Proteins; D009389:Neovascularization, Pathologic; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics; D015534:Trans-Activators; D051176:beta Catenin
D025601:Adenomatous Polyposis Coli Protein; C495270:CTNNB1 protein, human; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D003598:Cytoskeletal Proteins; D007527:Isoenzymes; D008565:Membrane Proteins; D015534:Trans-Activators; D051176:beta Catenin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases